The Association Between Human Epididymis Secretory Protein 4 and Metabolic Syndrome

Overview

Journal J Clin Med

Specialty General Medicine

Date 2022 May 14

PMID 35566488

Authors

Peng-Fei Li

Yu-Jen Lin

Yao-Jen Liang

Wei-Liang Chen

Affiliations

Soon will be listed here.

Abstract

Individuals with metabolic syndrome (MetS) are known to have an increased risk of carcinogenesis. Human epididymis protein 4 (HE4) is a tumor marker and prognostic factor for epithelial ovarian carcinoma (EOC) patients. However, no studies have evaluated the association between MetS and HE4 levels. This study aimed to evaluate the relationship between HE4 levels and MetS in the National Health and Nutrition Examination Survey (NHANES 2001−2002). This cross-sectional analysis assessed all five components of MetS and HE4 levels in 2104 females (age ≥20 years) from the NHANES dataset. MetS was defined according to the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATPIII) criteria. The analysis indicated MetS in 593 individuals, and the β coefficient of their HE4 levels was 0.097 (95% CIs, 0.028−0.166, p = 0.006). Specifically, the β coefficients of the HE4 levels of participants with 1, 2, 3, and ≥4 features of MetS were 0.072 (95% confidence interval (CI): −0.015−0.159), 0.125 (95% CI: 0.030−0.220), 0.161 (95% CI: 0.053−0.270), and 0.242 (95% CI: 0.117−0.368), respectively, and all p values were <0.001. The p-value for the trend was <0.001. There was a significant association between the presence of MetS and HE4 levels. There were positive relationships between HE4 levels and an increased number of MetS components (with 1, 2, 3, and ≥4 features of MetS, all p values <0.001). Among the MetS components, low high-density lipoprotein levels and high triglyceride levels were independently associated with HE4 levels.

References

Tian Y, Wang C, Cheng L, Zhang A, Liu W, Guo L . Determination of reference intervals of serum levels of human epididymis protein 4 (HE4) in Chinese women. J Ovarian Res. 2015; 8:72. PMC: 4637994. DOI: 10.1186/s13048-015-0201-z. View

Hirode G, Wong R . Trends in the Prevalence of Metabolic Syndrome in the United States, 2011-2016. JAMA. 2020; 323(24):2526-2528. PMC: 7312413. DOI: 10.1001/jama.2020.4501. View

Cowey S, Hardy R . The metabolic syndrome: A high-risk state for cancer?. Am J Pathol. 2006; 169(5):1505-22. PMC: 1780220. DOI: 10.2353/ajpath.2006.051090. View

Bolstad N, Oijordsbakken M, Nustad K, Bjerner J . Human epididymis protein 4 reference limits and natural variation in a Nordic reference population. Tumour Biol. 2011; 33(1):141-8. PMC: 3235278. DOI: 10.1007/s13277-011-0256-4. View

Chang X, Ye X, Dong L, Cheng H, Cheng Y, Zhu L . Human epididymis protein 4 (HE4) as a serum tumor biomarker in patients with ovarian carcinoma. Int J Gynecol Cancer. 2011; 21(5):852-8. DOI: 10.1097/IGC.0b013e31821a3726. View

De Nardo D, Labzin L, Kono H, Seki R, Schmidt S, Beyer M . High-density lipoprotein mediates anti-inflammatory reprogramming of macrophages via the transcriptional regulator ATF3. Nat Immunol. 2013; 15(2):152-60. PMC: 4009731. DOI: 10.1038/ni.2784. View

Esposito K, Chiodini P, Colao A, Lenzi A, Giugliano D . Metabolic syndrome and risk of cancer: a systematic review and meta-analysis. Diabetes Care. 2012; 35(11):2402-11. PMC: 3476894. DOI: 10.2337/dc12-0336. View

De Rosa S, Arcidiacono B, Chiefari E, Brunetti A, Indolfi C, Foti D . Type 2 Diabetes Mellitus and Cardiovascular Disease: Genetic and Epigenetic Links. Front Endocrinol (Lausanne). 2018; 9:2. PMC: 5776102. DOI: 10.3389/fendo.2018.00002. View

Huang Y, Jiang H, Zhu L . Human Epididymis Protein 4 as an Indicator of Acute Heart Failure in Patients with Chronic Kidney Disease. Lab Med. 2019; 51(2):169-175. DOI: 10.1093/labmed/lmz041. View

10.

Feingold K, Doerrler W, Dinarello C, Fiers W, Grunfeld C . Stimulation of lipolysis in cultured fat cells by tumor necrosis factor, interleukin-1, and the interferons is blocked by inhibition of prostaglandin synthesis. Endocrinology. 1992; 130(1):10-6. DOI: 10.1210/endo.130.1.1370149. View

11.

Yuan T, Li Y . Human Epididymis Protein 4 as a Potential Biomarker of Chronic Kidney Disease in Female Patients With Normal Ovarian Function. Lab Med. 2017; 48(3):238-243. DOI: 10.1093/labmed/lmx036. View

12.

Mohammadi M, Gozashti M, Aghadavood M, Mehdizadeh M, Hayatbakhsh M . Clinical Significance of Serum IL-6 and TNF-α Levels in Patients with Metabolic Syndrome. Rep Biochem Mol Biol. 2017; 6(1):74-79. PMC: 5643447. View

13.

Yanaranop M, Anakrat V, Siricharoenthai S, Nakrangsee S, Thinkhamrop B . Is the Risk of Ovarian Malignancy Algorithm Better Than Other Tests for Predicting Ovarian Malignancy in Women with Pelvic Masses?. Gynecol Obstet Invest. 2016; 82(1):47-53. DOI: 10.1159/000446238. View

14.

Puente D, Lopez-Jimenez T, Cos-Claramunt X, Ortega Y, Duarte-Salles T . Metabolic syndrome and risk of cancer: a study protocol of case-control study using data from the Information System for the Development of Research in Primary Care (SIDIAP) in Catalonia. BMJ Open. 2019; 9(6):e025365. PMC: 6575640. DOI: 10.1136/bmjopen-2018-025365. View

15.

Bjorge T, Lukanova A, Tretli S, Manjer J, Ulmer H, Stocks T . Metabolic risk factors and ovarian cancer in the Metabolic Syndrome and Cancer project. Int J Epidemiol. 2011; 40(6):1667-77. DOI: 10.1093/ije/dyr130. View

16.

Fahed G, Aoun L, Zerdan M, Allam S, Zerdan M, Bouferraa Y . Metabolic Syndrome: Updates on Pathophysiology and Management in 2021. Int J Mol Sci. 2022; 23(2). PMC: 8775991. DOI: 10.3390/ijms23020786. View

17.

Zipf G, Chiappa M, Porter K, Ostchega Y, Lewis B, Dostal J . National health and nutrition examination survey: plan and operations, 1999-2010. Vital Health Stat 1. 2014; (56):1-37. View

18.

Bovolini A, Garcia J, Andrade M, Duarte J . Metabolic Syndrome Pathophysiology and Predisposing Factors. Int J Sports Med. 2020; 42(3):199-214. DOI: 10.1055/a-1263-0898. View

19.

Romagnolo C, Leon A, Fabricio A, Taborelli M, Polesel J, Pup L . HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass: An Italian multicenter study. Gynecol Oncol. 2016; 141(2):303-311. DOI: 10.1016/j.ygyno.2016.01.016. View

20.

Jia L, Zhang Y, Li J, Tian Y, Li J . The role of human epididymis protein 4 in the diagnosis of epithelial ovarian cancer. Clin Transl Oncol. 2015; 18(3):233-9. DOI: 10.1007/s12094-015-1365-0. View